The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations.
J. Kim, F. Cai, B. Ko, C. Yang, H. M. Lee, N. Muhammad, K. Li, M. Haloul, W. Gu, B. Faubert, A. K. Kaushik, L. Cai, S. Kasiri, U. Marriam, K. Nham, , R. J. DeBerardinis
The paper identifies the hexosamine biosynthesis pathway as a metabolic vulnerability in KRAS/LKB1 mutant lung cancers and shows GFPT2 inhibition reduces tumor growth.
bioRxiv · Apr 13, 2020 · PreprintCancer Biology